Status: Open Not Enrolling
Investigator: Olga Waln
Study Coordinator: Yvonne Subhan
Phone: 346.238.9068
The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with ... Read more >
Status: Enrolling
Investigator: William Ondo
Study Coordinator: Chelsea Kinney
Phone: 346.238.9068
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. ... Read more >
Status: Enrolling
Investigator: William Ondo
Study Coordinator: Chelsea Kinney
Phone: 346.238.9068
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD. ... Read more >
Status: Enrolling
Investigator: Olga Waln
Study Coordinator: Yvonne Subhan
Phone: 346.238.9068
This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease. ... Read more >
Status: Enrolling
Investigator: Stanley Appel
Study Coordinator: Anjana Singh
Phone: 713.441.9120
The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neu ... Read more >